Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (NASDAQ: XENE) has announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units (PSUs). The grants, effective May 2, 2025, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.28 per common share, vesting over four years with a 10-year term. The PSUs will vest based on achieving predefined milestone-based objectives over approximately three years.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (XENE) has announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025) in San Diego. The company will showcase three key posters, highlighting significant progress in their epilepsy treatment research.
The main focus is on azetukalner, their novel Kv7 potassium channel opener, featuring 36-month long-term data from the ongoing X-TOLE open-label extension study in patients with focal onset seizures (FOS). The data demonstrates sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent safety profile.
Additional presentations include an exploratory analysis showing reduced seizure frequency across four focal seizure subtypes, and patient survey findings regarding mental health and comorbidity burdens of FOS. The presentations will take place between April 5-9, 2025, with Xenon also hosting booth #1110 in the Exhibit Hall.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum, scheduled for March 18-19, 2025. The company will deliver a fireside chat presentation, which will be accessible via live audio webcast on the 'Investors' section of Xenon's website.
Xenon specializes in developing ion channel product portfolio targeting areas with high unmet medical needs, particularly epilepsy and depression. Their leading product, Azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications. This compound represents the most advanced, clinically validated potassium channel modulator in development.
Xenon Pharmaceuticals (XENE) has provided its Q4 and full year 2024 financial results and business update. The company's lead drug candidate azetukalner is advancing in multiple Phase 3 trials, with topline data for focal onset seizures expected in H2 2025. The company is expanding its neuropsychiatric programs, with the first of three Phase 3 trials for major depressive disorder underway and plans to initiate bipolar depression studies mid-year.
Financial highlights include: Cash position of $754.4 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $210.4 million for 2024, up from $167.5 million in 2023. Net loss widened to $234.3 million in 2024 compared to $182.4 million in 2023.
The company announced CFO Sherry Aulin will step down on June 30, 2025. Additionally, Xenon's collaboration with Neurocrine Biosciences achieved a milestone with the initiation of a Phase 1 study of their Nav1.2/Nav1.6 inhibitor, triggering a $7.5 million payment.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the 45th Annual TD Cowen Healthcare Conference scheduled for March 3-5, 2025, in Boston, MA.
The company will provide a live audio webcast of their presentation, which will be accessible through the 'Investors' section of Xenon's website, with a replay option available post-event.
Xenon specializes in developing ion channel products targeting epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its fourth quarter 2024 financial results after U.S. market close on Thursday, February 27, 2025. The company will host a conference call and webcast, which will be available on the 'Investors' section of Xenon's website with a replay option following the event.
The company is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (XENE) has outlined significant milestones for 2025, highlighting progress in its pipeline programs. The company anticipates topline data from its first Phase 3 FOS study in H2 2025, marking a important step toward NDA filing for azetukalner. The company has initiated the first of three planned Phase 3 MDD studies and is advancing its ion channel portfolio.
Key developments include continued advancement of Phase 3 azetukalner clinical studies in focal onset seizures, with over 600 patient-years of data from the ongoing X-TOLE open-label extension study. The Phase 3 X-ACKT study for primary generalized tonic-clonic seizures (PGTCS) continues enrollment. Additionally, Xenon has launched X-NOVA2, the first of three Phase 3 trials for Major Depressive Disorder (MDD), with topline results from a Mount Sinai investigator-led study expected in H1 2025.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 13-16, 2025. The company's presentation will be delivered by Ian Mortimer, President and CEO, on Monday, January 13, 2025, from 9:45-10:25 AM Pacific Time.
As a neuroscience-focused biopharmaceutical company, Xenon is dedicated to developing therapeutics for areas of high unmet medical need, particularly in epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
The presentation will be accessible via live audio webcast through the 'Investors' section of Xenon's website, with a replay available after the event. The company focuses on advancing an ion channel product portfolio, emphasizing their commitment to discovering and delivering life-changing treatments for patients.
Xenon Pharmaceuticals presented new long-term data from its X-TOLE open-label extension (OLE) study of azetukalner for focal onset seizures at AES 2024. Key findings show that approximately one-third of patients on azetukalner for at least 36 months achieved seizure freedom for a year or longer, with sustained monthly seizure frequency reductions maintained at 85% at month 36.
The study demonstrated consistent tolerability and safety profile, with no new safety signals identified. Patient retention rates were 66%, 60%, and 52% at 12, 24, and 36 months respectively. Additional research presented highlighted significant mental health burdens in epilepsy patients and showed promising pre-clinical results for Nav1.1 potentiators in treating Dravet Syndrome.
Xenon Pharmaceuticals (XENE) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), scheduled for December 6-10, 2024 in Los Angeles. The company will present five posters featuring new long-term 36-month data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS). The presentations will also cover mental health and comorbidity burdens of FOS, along with new pre-clinical data from the company's early-stage Nav1.1 program. The company will host a Scientific Exhibit and maintain booths at the event to showcase their clinical and research programs.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
